SCHEMBL24101047

SCHEMBL24101047

BC(B)(C)OC(=O)C(Cc1ccc(F)cc1)NC(=O)C(N)Cc1ccc(N(CCCl)CCCl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.49
▸ CYP3A4 P08684 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ ABCB11 O95342 1/20 0.48
▸ CHRM2 P08172 1/20 0.48
▸ ADRA2A P08913 1/20 0.48
▸ CHRM1 P11229 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ OPRM1 P35372 1/20 0.48
▸ DRD3 P35462 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22567356 0.92 CYP3A4 (0.49) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL24506756 0.92 CYP3A4 (0.49) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL25021303 0.90 CYP3A4 (0.47) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL25022345 0.90 CYP3A4 (0.47) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL24100695 0.88 CYP3A4 (0.49) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL25021927 0.87 CYP3A4 (0.48) LMNACYP3A4KMT2AALDH1A1ALOX15
SCHEMBL22567450 0.87 LMNA (0.46) LMNACYP3A4KMT2AALDH1A1ALOX15
Melphalan Flufenamide SCHEMBL24101233 0.87 LMNA (0.53) LMNACYP3A4KMT2AALDH1A1ALOX15
Melphalan Flufenamide SCHEMBL20208719 0.87 LMNA (0.53) LMNACYP3A4KMT2AALDH1A1ALOX15
Melphalan Flufenamide SCHEMBL18239898 0.87 LMNA (0.53) LMNACYP3A4KMT2AALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3866931-B1 COMPOUNDS CONTAINING DEUTERIUM ONCOPEPTIDES AB (SE) 2023-02-15 — — EP disclosed
US-20210388024-A1 COMPOUNDS CONTAINING DEUTERIUM ONCOPEPTIDES AB (SE) 2021-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210388024-A1 COMPOUNDS CONTAINING DEUTERIUM DHX30, H1-10, REN LMNA 3001/4885CYP3A4 923/4885KMT2A 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback